middle.news
Imugene’s Azer-cel Shows Complete Response in BTKi-Resistant Follicular Lymphoma Patient
11:45am on Tuesday 30th of June, 2026 AEST
•
Healthcare
Read Story
Imugene’s Azer-cel Shows Complete Response in BTKi-Resistant Follicular Lymphoma Patient
11:45am on Tuesday 30th of June, 2026 AEST
Key Points
First complete response in BTKi-resistant follicular lymphoma
Azer-cel combined with BTKi targets a $12 billion market
Trial ongoing across US and Australian sites
Azer-cel offers off-the-shelf CAR T therapy advantage
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Imugene (ASX:IMU)
OPEN ARTICLE